Medibiom

In collaboration between Theralution, the Phytocompetence Centre (PKZ) and the Luxembourg Institute of Health (LIH), we are developing the future area of intestinal health.

What drives our development are our close links with science, the transfer of research findings into our product development with a view to sustainability and the value-creating integration into the MEDICE Health Family network. Together, we strive to improve people’s quality of life.

Nadja Neubauer

Vision

At the interface between science and medical practice, we research and develop pioneering diagnostic and solution programmes to become the market-leading expert in the field of microbiome and intestinal health in Germany.

Mission

In a future of personalised medicine, our health solutions are specifically tailored to the fingerprint of each individual’s gut microbiome to address the complexity of intestinal health for people.

Focus

The gut is very important for our health. It is not only where essential nutrients are prepared for use, but is also where the majority of the immune system can be found. Around 80% of all active immunocytes are in the gut. This makes it the largest immune organ in the body, playing a key role in the immune defence mechanism for the person’s overall health. It is the engine of our well-being. If it becomes imbalanced, many processes in the body can be blocked.

Theralution has now developed a special approach in order to promote intestinal health and offers anyone with gut-associated symptoms, defecation problems and food intolerances a dual nutritional counselling programme to practically implement a targeted, gut-healthy lifestyle – for greater quality of life! Thanks to a phased approach, all levels of the intestinal barrier are taken into account: intestinal flora, intestinal mucosa and intestinal wall cells.

The Theralution model is based on findings from LIH’s research activities. In close collaboration, it has already been possible to investigate the effects of our diet on the intestinal microbiome and thus on our intestinal function. The interaction between our immune system and the gut as the first protective barrier of our health system plays a central role in this.

In the future, too, we will conduct further studies in collaboration with LIH designed to provide information about the specific links between the microbiome structure, i.e. the entirety of the microorganisms in our gut, and the development of illnesses. By doing so, we are able to provide diagnostics that are relevant for both the doctor and patient.